GlobeNewswire: Ocera Therapeutics, Inc. Contains the last 10 of 135 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T02:26:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/11/02/1173296/0/en/Mallinckrodt-to-Acquire-Ocera-Therapeutics-and-OCR-002-its-Proprietary-Therapy-in-Development-for-Treatment-of-Hepatic-Encephalopathy.html?f=22&fvtc=4&fvtv=13555Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy2017-11-02T10:56:22Z<![CDATA[-- Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right ---- Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with hyperammonemia (excess ammonia in the blood) that occurs as complications of liver disease, such as cirrhosis --]]>https://www.globenewswire.com/news-release/2017/10/20/1150881/0/en/Ocera-Presents-Three-Posters-and-an-Oral-Presentation-on-OCR-002-at-the-AASLD-Liver-Meeting.html?f=22&fvtc=4&fvtv=13555Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®2017-10-20T11:30:00Z<![CDATA[REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine phenylacetate) in development for the treatment and prevention of hepatic encephalopathy (HE) will be presented at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 20-24, 2017, at the Washington Convention Center in Washington, D.C. Select findings from each presentation are cited below.]]>https://www.globenewswire.com/news-release/2017/08/23/1091513/0/en/Ocera-Therapeutics-Selected-to-Present-an-Oral-Presentation-and-Three-Posters-on-OCR-002-at-the-AASLD-Liver-Meeting-2017.html?f=22&fvtc=4&fvtv=13555Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 20172017-08-23T13:05:00Z<![CDATA[REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that four abstracts related to clinical study findings of OCR-002 (ornithine phenylacetate) in development for the treatment and prevention of hepatic encephalopathy (HE) have been selected for presentation at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held October 20-24, 2017, in Washington, D.C.]]>https://www.globenewswire.com/news-release/2017/08/01/1065756/0/en/Ocera-Therapeutics-Reports-Second-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=13555Ocera Therapeutics Reports Second Quarter 2017 Financial Results2017-08-01T20:05:00Z<![CDATA[REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development of OCR-002 for the treatment and prevention of hepatic encephalopathy (HE), a debilitating complication of liver disease and significant burden on the healthcare system, today reported financial results for the quarter ended June 30, 2017.]]>https://www.globenewswire.com/news-release/2017/06/01/1005409/0/en/Ocera-Initiates-Phase-2a-Study-with-Oral-OCR-002-in-Patients-with-Cirrhosis.html?f=22&fvtc=4&fvtv=13555Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis2017-06-01T13:05:00Z<![CDATA[Results Expected by Year-End 2017 Results Expected by Year-End 2017]]>https://www.globenewswire.com/news-release/2017/05/26/999321/0/en/Ocera-Therapeutics-to-Host-KOL-Conference-Call-on-Hepatic-Encephalopathy-and-Other-Complications-of-Liver-Disease-on-Friday-June-2.html?f=22&fvtc=4&fvtv=13555Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 22017-05-26T13:05:00Z<![CDATA[REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 26, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic liver diseases, today announced that it will host a Key Opinion Leader call on the topic of Hepatic Encephalopathy and Other Complications of Liver Disease, on Friday June 2, 2017 at 11:00 am Eastern Time.]]>https://www.globenewswire.com/news-release/2017/05/09/981404/0/en/Ocera-Therapeutics-Reports-First-Quarter-2017-Financial-Results-and-Provides-Clinical-Update.html?f=22&fvtc=4&fvtv=13555Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update2017-05-09T20:05:00Z<![CDATA[Post-hoc per protocol analysis demonstrates OCR-002 achieved primary endpoint with statistical significance, p=0.034]]>https://www.globenewswire.com/news-release/2017/05/03/978157/0/en/Ocera-Therapeutics-to-Report-First-Quarter-2017-Financial-Results-and-Provide-Clinical-Update-on-May-9-2017.html?f=22&fvtc=4&fvtv=13555Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 20172017-05-03T20:05:00Z<![CDATA[REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 03, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will report its first quarter 2017 financial results and provide a clinical update on May 9, 2017. In conjunction with this announcement, Ocera will host a conference call and live audio webcast on May 9, 2017 at 4:30 p.m. Eastern Time to both review the financial results and provide an update on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE), a debilitating liver disorder and significant burden on the healthcare system.]]>https://www.globenewswire.com/news-release/2017/04/12/959994/0/en/Ocera-Therapeutics-Announces-Presentation-of-Data-Showing-OCR-002-Prevented-Progression-of-Fibrosis-in-Preclinical-Model-of-Non-alcoholic-Fatty-Liver-Disease-NAFLD.html?f=22&fvtc=4&fvtv=13555Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)2017-04-12T20:05:00Z<![CDATA[Supports potential for OCR-002 in the treatment of NAFLD/NASH]]>https://www.globenewswire.com/news-release/2017/03/27/945572/0/en/Ocera-to-Present-at-the-16th-Annual-Needham-Healthcare-Conference.html?f=22&fvtc=4&fvtv=13555Ocera to Present at the 16th Annual Needham Healthcare Conference2017-03-27T20:05:00Z<![CDATA[-- Company Presentation Scheduled for April 4, 2017 at 4:20 PM ET -- -- Company Presentation Scheduled for April 4, 2017 at 4:20 PM ET --]]>